Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tofacitinib for the Treatment of Inflammatory Eye Disease

Trial Profile

Tofacitinib for the Treatment of Inflammatory Eye Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2019

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Scleritis; Uveitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Jan 2019 Planned number of patients changed from 15 to 5.
    • 24 Jan 2019 Status changed from not yet recruiting to recruiting.
    • 12 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top